These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 22043044)

  • 41. Strategies to translate preclinical information to breast cancer patient benefit.
    Daidone MG; Zaffaroni N; Cappelletti V
    J Natl Cancer Inst Monogr; 2011; 2011(43):55-9. PubMed ID: 22043041
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Dynamic contrast-enhanced magnetic resonance imaging and blood oxygenation level-dependent magnetic resonance imaging for the assessment of changes in tumor biology with treatment.
    Li SP; Padhani AR; Makris A
    J Natl Cancer Inst Monogr; 2011; 2011(43):103-7. PubMed ID: 22043053
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Systemic neoadjuvant therapy of luminal breast cancer in 2016].
    Cottu PH
    Bull Cancer; 2017 Jan; 104(1):69-78. PubMed ID: 27817858
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Template for reporting results of biomarker testing of specimens from patients with carcinoma of the breast.
    Fitzgibbons PL; Dillon DA; Alsabeh R; Berman MA; Hayes DF; Hicks DG; Hughes KS; Nofech-Mozes S
    Arch Pathol Lab Med; 2014 May; 138(5):595-601. PubMed ID: 24236805
    [No Abstract]   [Full Text] [Related]  

  • 45. Neoadjuvant Treatment Approach: The Rosetta Stone for Breast Cancer?
    Generali D; Ardine M; Strina C; Milani M; Cappelletti MR; Zanotti L; Forti M; Bedussi F; Martinotti M; Amoroso V; Sigala S; Simoncini E; Berruti A; Bottini A
    J Natl Cancer Inst Monogr; 2015 May; 2015(51):32-5. PubMed ID: 26063883
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Systemic Therapies for Nonmetastatic Breast Cancer: The Role of Neoadjuvant and Adjuvant Chemotherapy and the Use of Endocrine Therapy.
    Bychkovsky BL; Dizon DS; Sikov WM
    Clin Obstet Gynecol; 2016 Dec; 59(4):756-771. PubMed ID: 27741213
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Proteomic approach reveals FKBP4 and S100A9 as potential prediction markers of therapeutic response to neoadjuvant chemotherapy in patients with breast cancer.
    Yang WS; Moon HG; Kim HS; Choi EJ; Yu MH; Noh DY; Lee C
    J Proteome Res; 2012 Feb; 11(2):1078-88. PubMed ID: 22074005
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Bridging the gap between translational research and clinical application.
    Miller WR; Larionov AA
    J Natl Cancer Inst Monogr; 2011; 2011(43):134-7. PubMed ID: 22043060
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Molecular phenotypes of breast cancer and their clinical application].
    Tang P; Wei B; Hicks DG; Skinner K; Bu H
    Zhonghua Bing Li Xue Za Zhi; 2009 Jan; 38(1):13-7. PubMed ID: 19489219
    [No Abstract]   [Full Text] [Related]  

  • 50. Next-generation targeted agents in HER2-positive metastatic breast cancer.
    Perez EA
    Clin Adv Hematol Oncol; 2012 Jul; 10(7):465-7. PubMed ID: 22895288
    [No Abstract]   [Full Text] [Related]  

  • 51. Personalized-medicine trials on the rise.
    Benowitz S
    J Natl Cancer Inst; 2012 Oct; 104(19):1425-6. PubMed ID: 23008496
    [No Abstract]   [Full Text] [Related]  

  • 52. Immunohistochemistry in the era of personalised medicine.
    McCourt CM; Boyle D; James J; Salto-Tellez M
    J Clin Pathol; 2013 Jan; 66(1):58-61. PubMed ID: 23002284
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Genomics and clinical research for breast cancer].
    Bertucci F; Birnbaum D
    Med Sci (Paris); 2012 Mar; 28 Spec No 1():14-8. PubMed ID: 22494651
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Progress in breast cancer: overview.
    Arteaga CL
    Clin Cancer Res; 2013 Dec; 19(23):6353-9. PubMed ID: 24298065
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Personalized medicine: present and future of breast cancer management.
    Sabatier R; Gonçalves A; Bertucci F
    Crit Rev Oncol Hematol; 2014 Sep; 91(3):223-33. PubMed ID: 24725667
    [TBL] [Abstract][Full Text] [Related]  

  • 56. TAILORx: trial assigning individualized options for treatment (Rx).
    Sparano JA
    Clin Breast Cancer; 2006 Oct; 7(4):347-50. PubMed ID: 17092406
    [No Abstract]   [Full Text] [Related]  

  • 57. [Personalized medicine and breast cancer: anticipatory medicine, prognostic evaluation and therapeutic targeting].
    Gonçalves A; Moretta J; Eisinger F; Bertucci F
    Bull Cancer; 2013 Dec; 100(12):1295-310. PubMed ID: 24225763
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Novel targeted therapies for the treatment of penile cancer.
    Agarwal G; Gupta S; Spiess PE
    Expert Opin Drug Discov; 2014 Aug; 9(8):959-68. PubMed ID: 24896220
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Lessons for tumor biomarker trials: vicious cycles, scientific method & developing guidelines.
    Hayes D; Raison C
    Expert Rev Mol Diagn; 2015 Feb; 15(2):165-9. PubMed ID: 25548983
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Foundation clinical trials.
    Cameron D
    Breast Cancer Res; 2009; 11 Suppl 3(Suppl 3):S23. PubMed ID: 20030875
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.